VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Stock Comparison

American Express Company vs Sanofi

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

American Express Company

AXP · New York Stock Exchange

Market cap (USD)$215.3B
Gross margin (TTM)83.5%
Operating margin (TTM)20.7%
Net margin (TTM)13.6%
SectorFinancials
IndustryFinancial - Credit Services
CountryUS
Data as of2026-04-25
Moat score
76/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into American Express Company's moat claims, evidence, and risks.

View AXP analysis

Sanofi

SAN · Euronext Paris

Market cap (USD)$113.7B
Gross margin (TTM)71.7%
Operating margin (TTM)25.4%
Net margin (TTM)18.2%
SectorHealthcare
IndustryDrug Manufacturers - General
CountryFR
Data as of2025-12-30
Moat score
74/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Sanofi's moat claims, evidence, and risks.

View SAN analysis

Comparison highlights

  • Moat score gap: American Express Company leads (76 / 100 vs 74 / 100 for Sanofi).
  • Segment focus: American Express Company has 4 segments (48% in U.S. Consumer Services); Sanofi has 3 segments (79.8% in Pharma (Prescription Medicines)).
  • Primary market structure: Oligopoly vs Oligopoly. Pricing power: Strong vs Moderate.
  • Moat breadth: American Express Company has 7 moat types across 3 domains; Sanofi has 5 across 3.

Primary market context

American Express Company

U.S. Consumer Services

Market

U.S. premium consumer credit, charge, banking, lending, travel, dining and lifestyle card services

Geography

United States

Customer

Affluent and mass-affluent U.S. consumers

Role

Issuer, lender, rewards platform, banking provider, travel/dining service provider and closed-loop network participant

Revenue share

48%

Sanofi

Pharma (Prescription Medicines)

Market

Branded prescription pharmaceuticals (immunology, rare disease, neurology, oncology, general medicines)

Geography

Global

Customer

Patients via payers/providers and channel partners (wholesalers, pharmacies, hospitals)

Role

Research-based drug developer, manufacturer, and marketer

Revenue share

79.8%

Side-by-side metrics

American Express Company
Sanofi
Ticker / Exchange
AXP - New York Stock Exchange
SAN - Euronext Paris
Market cap (USD)
$215.3B
$113.7B
Gross margin (TTM)
83.5%
71.7%
Operating margin (TTM)
20.7%
25.4%
Net margin (TTM)
13.6%
18.2%
Sector
Financials
Healthcare
Industry
Financial - Credit Services
Drug Manufacturers - General
HQ country
US
FR
Primary segment
U.S. Consumer Services
Pharma (Prescription Medicines)
Market structure
Oligopoly
Oligopoly
Market share
10.5%-11% (implied)
n/a
HHI estimate
n/a
n/a
Pricing power
Strong
Moderate
Moat score
76 / 100
74 / 100
Moat domains
Demand, Network, Supply
Legal, Supply, Demand
Last update
2026-04-25
2025-12-30

Moat coverage

Shared moat types

Brand Trust

American Express Company strengths

Habit DefaultData Network EffectsData Workflow LockinProcurement InertiaScope EconomiesTwo Sided Network

Sanofi strengths

Regulated Standards PipeIP Choke PointLearning Curve YieldDistribution Control

Segment mix

American Express Company segments

Full profile >

U.S. Consumer Services

Oligopoly

48%

Commercial Services

Oligopoly

23.4%

International Card Services

Competitive

17.9%

Global Merchant and Network Services

Oligopoly

10.7%

Sanofi segments

Full profile >

Pharma (Prescription Medicines)

Oligopoly

79.8%

Vaccines

Oligopoly

20.2%

Opella (Consumer Healthcare - Sanofi minority stake)

Competitive

n/a

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Looking for expansion-stage stocks?

Proven models entering the expansion stage with unit economics that work.

View expansion-stage stocks

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.